SCHEMBL1879696

SCHEMBL1879696

NCCCOCc1ccccc1-c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.53
GBA1 P04062 2/20 0.47
LCT P09848 2/20 0.47
SI P14410 2/20 0.47
UGCG Q16739 2/20 0.47
GBA2 Q9HCG7 2/20 0.47
MGAM O43451 1/20 0.47
TACR1 P25103 1/20 0.47
CHRNB2 P17787 2/20 0.46
CHRNA4 P43681 2/20 0.46
TP53 P04637 1/20 0.45
MAPK1 P28482 1/20 0.45
RAB9A P51151 1/20 0.45
CHRNB4 P30926 1/20 0.41
CHRNA3 P32297 1/20 0.41
KMT2A Q03164 1/20 0.39
FFAR4 Q5NUL3 3/20 0.38
FFAR1 O14842 2/20 0.38
SCN8A Q9UQD0 1/20 0.38
CARM1 Q86X55 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27373494 0.83 GBA1 (0.47) DPP4GBA1LCTSIUGCG
SCHEMBL27823404 0.81 GBA1 (0.49) DPP4GBA1LCTSIUGCG
SCHEMBL336977 0.81 TACR1 (0.62) DPP4GBA1LCTSIUGCG
SCHEMBL8871794 0.80 TACR1 (0.50) DPP4GBA1LCTSIUGCG
SCHEMBL27802636 0.80 GBA1 (0.51) DPP4GBA1LCTSIUGCG
SCHEMBL27914973 0.79 TACR1 (0.49) DPP4GBA1LCTSIUGCG
SCHEMBL9338655 0.77 TACR1 (0.58) DPP4GBA1LCTSIUGCG
SCHEMBL2489577 0.77 GBA1 (0.35) DPP4GBA1LCTSIUGCG
SCHEMBL2493521 0.77 CD274 (0.35) DPP4GBA1LCTSIUGCG
SCHEMBL28257937 0.77 TACR1 (0.48) DPP4GBA1LCTSIUGCG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1870396-B1 BENZYLOXYPROPYLAMINE DERIVATIVE NIPPON ZOKI PHARMACEUTICAL CO (JP) 2012-10-31 EP disclosed
US-7939552-B2 Tachykinin receptor anatgonist; good transfer into blood; long half-life; stability; bradycardial agents; antiinflammatory agents ; antallergens; analgesics; antiemetics; irritable bowel disorders; skin disorders; antidepressants; antiischemic agents ; anxiolytic agents; autoimmune diseases; muscle relax NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 2011-05-10 US disclosed
US-20080262230-A1 Benzyloxypropylamine Derivative NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 2008-10-23 US disclosed
EP-1870396-A1 BENZYLOXYPROPYLAMINE DERIVATIVE Nippon Zoki Pharmaceutical Co. Ltd. (JP) 2007-12-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262230-A1 Benzyloxypropylamine Derivative BDKRB2, BDKRB1, PNMT DPP4 910/4885GBA1 2084/4885LCT 3548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.